Pharma sponsors · CROs

Available

Enrollment slots

below industry average

Screen failure rate

Registered studies — FDAAA 801

high accuracy

Criterion classification

Pre-screened candidates. Criterion-by-criterion documentation. Companion diagnostic channel outside Medicare.

TrialChecker classifies each patient-trial pair field by field — mutation status, ECOG, prior therapy lines, organ function thresholds — against published eligibility criteria. Any structured genomic result is accepted. Candidates arrive pre-documented, criterion-matched, physician-referred. Screen failure rate: under 5%. Industry average: the industry average.

Sponsor inquiry

Mechanism

Genomic result to enrolled candidate — four steps.

Criterion-by-criterion candidate identification

TrialChecker evaluates each patient-trial pair criterion by criterion against published eligibility criteria. Mutation status, ECOG performance, prior therapy lines, organ function thresholds — each criterion checked against patient-specific values. Candidates delivered with field-by-field eligibility documentation. high accuracy. Evaluated on real EHR data at Dana-Farber Cancer Institute.

Panel-agnostic genomic input

multi-gene ctDNA panel, Guardant360, Tempus xF+, Foundation Medicine, or tissue CGP. Any structured genomic result is accepted. SNVs, indels, copy number alterations, MSI. low VAF sensitivity on the Atumnus panel. Processed at partner lab under existing CLIA certification. Gene-to-therapy matrix maps output to registered trial eligibility criteria.

Registered registered studies — ClinicalTrials.gov FDAAA 801

Atumnus LLC. IRB-approved protocols. Available enrollment slots. Companion diagnostic testing channel operates outside Medicare billing. Flat-fee companion diagnostic — per sponsor agreement — sponsor to lab, direct. Enrollment Q3 2026. No data sharing required from sponsor.

Independent physician sub-investigator network

Credentialed urologists, oncologists, and hematology/oncology physicians. NPI-direct credentialing in 48 hours. No hospital affiliation required. Sub-investigator agreements on Atumnus-registered studies. 53% of US urologists practice outside institutional networks — 2024 AMA/Physicians Advocacy Institute data. Physician manages all enrollment and eligibility determination.

Channel specifications

Channel parameters.

Enrolled slots

Available across Registered studies

Sponsor payment

Flat-fee — per agreement

Screen failure

Under 5% (industry avg. the industry average)

Panel input

Any structured genomic result

Indications

Prostate · Bladder · RCC

Bioregulator studies

Registered registered, Q3 2026

AUROC

Peer-reviewed accuracy

Data sharing

None required from sponsor

Bioregulator study registry

Registered registered observational studies. Enrollment opens Q3 2026.

Atumnus LLC. ClinicalTrials.gov. FDAAA 801. IRB-approved protocols. BPC-157, MOTS-c, Epithalon, Semax, KPV, and 22 additional compounds. No current ClinicalTrials.gov matching platform indexes this compound category. Companion diagnostic testing channel available to sponsors outside Medicare billing.

BPC-157

4 studies

Musculoskeletal, gut mucosa

MOTS-c

3 studies

Metabolic function, mitochondrial

Epithalon

4 studies

Telomere biology, circadian

Semax

3 studies

Neuroprotection, cognitive

KPV

3 studies

Inflammation, mucosal repair

Additional compounds

10 studies

See registry

Sponsor inquiry

Companion diagnostic testing inquiry

Inquiries reviewed within 5 business days. Include the indication, phase, and approximate enrollment target. Existing panel relationships do not affect eligibility for the channel.